Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
While sommarutide is undoubtedly an exciting potential treatment option, there is still a lack of clear clinical data on the mechanism of action of GLP-1 agonists in NASH, such as whether GLP-1 agonists have a direct, independent role in improving NASH, or simply by improving body weight, insulin resistance, and so on
Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS
Addressing the Challenges: A Call for Comprehensive Care The recent findings demand a strategic approach to prescribing Ozempic and its counterparts, emphasizing the importance of mental health evaluations and patient-physician communication
The data stops in 2022, before tirzepatide, sold as Zepbound and Mounjaro, won approval for weight loss and before Medicare offered eligible seniors weight-loss drugs for a flat $50 monthly copay
